Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study
Cancers | Free Full-Text | Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
Cancers | Free Full-Text | Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
Progression-free survival: panitumumab compared with best supportive... | Download Scientific Diagram
Safety and Efficacy of Panitumumab in the Treatment of Metastatic Colorectal Cancer - Daniel J. Freeman, 2009
Panitumumab Combined With FOLFOX Emerges As the New First-Line PARADIGM for Left-Sided RAS Wild-Type Metastatic Colorectal Cancer
KaplaneMeier curves for overall survival by presence or absence of... | Download Scientific Diagram
Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients | Anticancer Research
Figure 1 from Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies | Semantic Scholar
Overall survival by severity of skin rash in patients with third-line... | Download Scientific Diagram
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer - ScienceDirect
An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer | SpringerLink
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study
Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer - Medical Conferences
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer | NEJM
In Metastatic RAS Wild-Type Left-Sided Colorectal Cancer, Panitumumab Proves Superior to Bevacizumab - The ASCO Post
ASCO-GI 2023: Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial.
Overall survival from randomisation in (a) PRIME, (b) PEAK and (c)... | Download Scientific Diagram
Panitumumab Combined With FOLFOX Emerges As the New First-Line PARADIGM for Left-Sided RAS Wild-Type Metastatic Colorectal Cancer
![PDF] Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/83d238981a0fb4261d1ccb37391284312cb0fd5e/5-Figure2-1.png "PDF] Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status | Semantic Scholar")
PDF] Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status | Semantic Scholar
